



News Release

February 16th, 2021

FOR IMMEDIATE RELEASE

BiocurePharm, Korea ("BPK") Announces the Appointment of a New Independent Director, Mr. Berkan Unal

VANCOUVER, British Columbia, February 16th, 2021-- Biocure Technology Corp. ("CURE" or the "Company") (CSE:CURE; OTCQB: BICTF) is pleased to announce that Mr. Berkan Unal has joined the Board of Directors as an Independent Director, effective immediately. He will replace Mr. Hans Frykman, whom was a valuable asset to our Board for 3 years. We wish him continued success and thank him for his service.

Mr. Unal brings an impressive and diverse resume, including over 10 years of experience in the biopharmaceutical industry and solid connections to global leaders in the bio-pharmaceutical sector. He studied bioprocess engineering and medical biotechnology at the Berlin Technical University of Applied Sciences, Hamburg University of Technology and the Imperial College London.

Currently, he is acting and will continue, as the Business Development Director for Biologics, Gene and Cell Therapy of GenScript Biotech. Both are global leading biotech companies and Mr. Unal has been involved in the processes which provides end-to-end solutions from discovery to commercialization. His experience is a welcomed addition to our team. Prior to joining GenScript Biotech, he worked for biotech companies in Switzerland and Germany.

Dr. Sang Mok Lee, CEO and President of Biocure and BPK, states "We would like to thank Mr. Frykman for his invaluable contribution to the Board throughout his tenure and wish him continued success in his endeavors. As we move the Company forward from discovery to commercialization, we welcome Mr. Berkan Unal's broad experience to assist the Company's Management in realizing our business model which could enable European ALL patients with an affordable CAR T Therapy to save more lives."

The company also has granted 6,020,000 options at 0.30 for three years vesting immediately.

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem

known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, and a hair growth production product.

ON BEHALF OF THE BOARD OF DIRECTORS

/S/ “SANG MOK LEE”
CEO and Director

For further information, please contact:
Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com

Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.